Germany's Economy Ministry blocks Volkswagen deal with Chinese company on national security grounds; China leads the world in the adoption of generative AI in banking and healthcare; and Chinese filmmakers wishing to submit short films to overseas film festivals must first register with authorities.
The U.S. has added additional Chinese companies to its Entity List and Unverified List; China's State Council has taken steps to encourage foreign venture capital in the tech sector; and Chinese electrolyzer manufacturers are "Europeanizing" their products in anticipation of an EU crackdown.
Shanghai FTZ elaborates on the general data of the biomedical sector
The U.S. publishes details on "Reverse CFIUS;" Shein's London listing might face obstacles; and two of the top 10 VC deals globally involve China, with much of the funding coming from Chinese state-backed investors.
Alleged receiving of kickbacks by senior executives in China could subject Adidas to Chinese, as well as German and U.S. investigations; U.S. convertible bond market is used to raise funds by Chinese big tech amid IPO restrictions; and EU tariffs may lead to localization of Chinese EV production.
Philip Qu and Qiuchen Wang from TransAsia Lawyers analyze a pioneering approach to regulating cross-border data transfers recently adopted in one of Shanghai's free trade zones
Apple wins antitrust case in China over app store fees; Temu is now subject to stricter EU online content rules; and Record Chinese investments flow into Mexico and Vietnam amid Western trade tensions.
Shanghai FTZ elaborates on the general data of the public fund sector
Fang Jianwei, Lv Chao and Yuan Chenhao of Zhong Lun Law Firm in Shanghai explain the background and impact – including on multinational companies – of a set of new rules governing the local production of imported drugs
Western companies are investing in Chinese biotech even amid continued geopolitical tension between China and the West and decreasing appetite for foreign investment in China; Two lithium battery part manufacturers, Capchem and Kedaliplan, plan to build factories in the U.S. to avoid hefty lithium battery tariffs; and Chinese pharma firm Asymchem to take over U.K. Pfizer plant.
